Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | BLK | P51451 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 15/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328751 | 0.86 | TEAD1 (0.45) | JAK3BTKFGFR1FGFR2TEAD1 | |
| SCHEMBL23328325 | 0.86 | FGFR1 (0.41) | JAK3EGFRBTKFGFR1FGFR2 | |
| SCHEMBL24518644 | 0.79 | TDP1 (0.36) | JAK3EGFRERBB2BLKBTK | |
| SCHEMBL24037593 | 0.78 | KMT2A (0.36) | JAK3EGFRERBB2BLKBTK | |
| SCHEMBL19889001 | 0.76 | FGFR1 (0.41) | JAK3EGFRERBB2BLKBTK | |
| SCHEMBL25900314 | 0.76 | FGFR1 (0.38) | JAK3EGFRERBB2BLKBTK | |
| SCHEMBL23364561 | 0.75 | LIPG (0.37) | — | |
| SCHEMBL23364562 | 0.75 | LIPG (0.37) | — | |
| SCHEMBL23328995 | 0.75 | EGFR (0.41) | JAK3EGFRERBB2BLKBTK | |
| SCHEMBL23328268 | 0.73 | TEAD1 (0.38) | TEAD1TEAD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | JAK3 196/4885EGFR 43/4885ERBB2 37/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | JAK3 153/4885EGFR 44/4885ERBB2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.